Steve Aselage

Steve Aselage was appointed to the Board in January 2019. Mr. Aselage most recently served as chief executive officer of Travere Therapeutics, a biopharmaceutical company specializing in identifying, developing, and delivering life-changing therapies to people living with rare diseases, which he joined in 2012. He has more than 40 years of experience in the biopharmaceutical industry, including substantial rare disease, commercial, and business development experience. From 2005 to 2012, Mr. Aselage served as executive vice president and chief business officer of BioMarin. Prior to BioMarin, Mr. Aselage held positions of increasing responsibility at a number of companies, including Bristol Laboratories, Genentech, and Sangstat. He currently continues to serve on the board of Travere, as chairman of Acer Therapeutics, and on the advisory council of the University of Notre Dame Department of Science.